BioWorld

Dec. 11, 2009

Cytokinetics Is All Muscle: Ends Cancer Deal with GSK

A year after GlaxoSmithKline plc backed away from two cancer drugs covered under its collaboration with Cytokinetics Inc., the big pharma handed back rights to the third and final compound as well. (BioWorld Today) Read More

New Trial a Show of Confidence for Oncothyreon Cancer Vaccine

Plaques, Bad Cholesterol Get Partial Rehab in Alzheimer's

Despite Concerns, Panel Backs Gilead Inhaled Aztreonam in CF

Financings Roundup

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 6, 2025.

DNA mutations or genetic disorder concept art

Regenxbio’s Duchenne gene therapy data positive as shares falter

BioWorld

Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...

EMA warns Ozempic linked to ‘very rare’ side effect

BioWorld

The EMA’s safety committee has issued a warning that the GLP-1 receptor agonist Ozempic (semaglutide, Novo Nordisk A/S) can cause an acute eye condition in which...

Aiatella secures €2M for AI-based cardiovascular imaging tech

BioWorld MedTech

Aiatella Oy secured €2 million (US$2.28 million) in funding for its AI-powered cardiovascular imaging technology. The funds will be used to conduct clinical...